Assertio Therapeutics Inc (Nasdaq:ASRT)
December 7th, 2018
Amidst falling markets Assertio Therapeutics Inc fell $0.23 Friday, a 5.11% decline, closing at $4.27. As well as the drop in value, Assertio Therapeutics Inc hit a new 52 week low of $4.22.
ASRT was outperformed by the rest of the Healthcare sector which went down only 2.51%.
The market sectors were mixed Friday with a majority of the sectors trending down. Utilities saw the biggest increase of the day (0.40%), while Information Technology saw the biggest drop (3.53%). Healthcare has seen the biggest year-to-date gain at 12%. The biggest loss this year has been the Materials sector dropping 12%.
Utilities saw the biggest turnaround from its 5-day performance of 2.33%, as it went up 0.40%. Real Estate saw a turn around from its 5-day performance of 2.84% trading down 1.44%.
- Utilities went up with a 0.40% change.
- Energy went down with a -0.64% change.
- Consumer Staples went down with a -1.29% change.
- Real Estate went down with a -1.44% change.
- Financials went down with a -1.84% change.
- Communication Services went down with a -2.09% change.
- Healthcare went down with a -2.51% change.
- Materials went down with a -2.54% change.
- Industrials went down with a -2.62% change.
- Consumer Discretionary went down with a -3.08% change.
- Information Technology went down with a -3.53% change.
Assertio Therapeutics Inc Info
Assertio Therapeutics, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults. The company also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, it is involved in the clinical development of Cebranopadol for the treatment of chronic nociceptive and neuropathic pain. It has a collaboration and license agreement with Ironwood Pharmaceuticals, Inc.; and a license agreement with Janssen Pharmaceuticals, Inc. based on its proprietary Acuform gastroretentive drug delivery technology. The company sells its products to wholesalers and retail pharmacies. The company was formerly known as Depomed Inc. and changed its name to Assertio Therapeutics, Inc. in August 2018 Assertio Therapeutics, Inc. was founded in 1995 and is headquartered in Lake Forest, Illinois.
All amounts in USD unless otherwise indicated
Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.